Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

计划入组 1,600 人 · 首次发布于 2023 年 6 月 12 日

ClarVista HARMONI Toric Trial With Intraoperative Exchange

计划入组 44 人 · 首次发布于 2017 年 2 月 15 日

Yoga Asana Chandra Harmoni on Psychological Well-being and Learning Readiness Among Medical Students

计划入组 80 人 · 首次发布于 2025 年 9 月 12 日

Oxybenzone(Meijer)

C₁₄H₁₂O₃

BE-3-3-3-3

Indole-3-carbinol

C₉H₉NO

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

Summit Therapeutics' Phase 3 HARMONi Trial Poised for Mid-2025 Readout in Duchenne Muscular Dystrophy

Summit Therapeutics Submits BLA for Ivonescimab in EGFR-Mutated NSCLC as Analysts Spotlight Phase III Pipeline

Summit Therapeutics Advances Ivonescimab Program with Pfizer Collaboration and Phase III Trial Progress in NSCLC